About STELIS Biopharmaceuticals
STELIS Biopharma Pvt. Ltd. is a fully-owned subsidiary of Strides set up in 2013 to consolidate and augment the R&D activities of Inbiopro, which was fully acquired in 2012; and in extending the value chain to manufacturing and commercialisation of the product pipeline.
STELIS is pursuing a blended strategy of-
developing both ‘biosimilars’ and ‘novel biotherapeutics’ to a ‘Regulated’ market (US/EU) standard for global markets. Our strategy is to offer high-quality bio-pharmaceuticals at affordable prices initially in high-growth Emerging Markets whose vast patient populations offer un-paralleled opportunities for expanded access.
We are shortly moving to a 22,000 sq. ft. state-of-the art R&D facility in Bangalore dedicated to bio-pharmaceuticals. This advanced facility will house 60 scientists and will incorporate the latest in bio-process engineering and bio-analytical techniques and support process development in both microbial and mammalian expression systems.
STELIS has partnered with Malaysian Bio-XCell Sdn. Bhd., an industrial biotech technology park and ecosystem, to set up an advanced bio-therapeutic manufacturing facility using ‘next-generation’ manufacturing and bio-process technologies which will revolutionise the way bio-molecules are manufactured. The plant, which is expected to come online in mid-2015, will have capability to produce simple and complex bio-therapeutics using microbial and mammalian systems. It will also have fill-finish capability in a variety of formats.